Navigation Links
Nasdaq Informs Synutra that the Company's Filing Delinquency has been Cured
Date:10/11/2007

QINGDAO, China and ROCKVILLE, Md., Oct. 11 /Xinhua-PRNewswire/ -- On October 10, 2007, Synutra International, Inc. (Nasdaq: SYUT; "Synutra"), one of China's leading manufacturers of dairy-based nutritional products for infants, children and adults, received a letter from the Nasdaq Stock Market stating that the Company's common stock is no longer subject to delisting following the filing with the SEC on October 5, 2007 of the Company's quarterly report on Form 10-Q for the period ended June 30, 2007. Upon review of the filing, the Nasdaq staff determined that Synutra meets all listing criteria and is in compliance with Nasdaq Marketplace Rule 4310(c)(14), which states that timely filing of annual and periodic reports with the SEC is required for continued listing. Accordingly, the Company's scheduled hearing before Nasdaq's Listing Qualifications Panel has been considered moot.

About Synutra International, Inc.

Synutra operates eight subsidiaries developing, producing, distributing and selling dairy-based nutritional products across the People's Republic of China. It offers its products for infants, children, adults and pregnant women and nursing mothers under the brand series of "Super," "U-Smart" and "U- Strong." The Group's extensive sales network covers 24 provinces, 264 cities and more than 1320 counties throughout China. For more information, please contact Weiguo Zhang of Synutra, Inc. (+1-301-840-3888, wzhang@synutra.com), Brian Rafferty of Taylor Rafferty (+1-212-889-4350, synutra@taylor-rafferty.com) or visit: http://www.synutra.com.

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward- looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

For more information, please contact:

Mr. Weiguo Zhang, Synutra, Inc.

Phone: +1-301-840-3888

Email: wzhang@synutra.com

Mr. Brian Rafferty

Taylor Rafferty

Phone: +1-212-889-4350

Email: synutra@taylor-rafferty.com


'/>"/>
SOURCE Synutra International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Patna To Receive Better Health Care Facility Informs Health Minister
2. Nutrient Profiling System Launched By Food Officials in UK
3. Proteomic Profiling Can Detect Preterm Birth Risk
4. Brains Filing System Uncovered
5. Profiling of Cancer Genes May Lead to Earlier Detection Human Cancers
6. Sweaty palms syndrome can be cured by surgery
7. Muscular Dystrophy May Be Cured By Gene Therapy
8. Back injury cured by engineers
9. Multiple organ disease cured by genes
10. Hay fever may be cured by self-hypnosis
11. Women cured of anorexia nervosa have redistributed body fat after weight gain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... development of Physiocrine-based therapeutics to address severe, rare diseases, today announced ... upcoming BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay ... December 14, 2016, at 4:20 p.m. ET. About ... ...
(Date:12/9/2016)... , Dec. 9, 2016 Department of Health ... regulations for medical marijuana dispensaries under Act 16 are ... , and are now available online . ... in the plan for operation; process for dispensing medical ... well as where the dispensary facilities can be located," ...
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
Breaking Medicine Technology: